Compare XMAX & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XMAX | ARVN |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.8M | 600.2M |
| IPO Year | 2009 | 2018 |
| Metric | XMAX | ARVN |
|---|---|---|
| Price | $5.85 | $6.74 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | ★ 1.2M | 879.9K |
| Earning Date | 11-13-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.51 | 58.84 |
| EPS | 0.42 | ★ 0.88 |
| Revenue | $12,744,871.00 | ★ $262,600,000.00 |
| Revenue This Year | N/A | $5.67 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.42 | ★ $7.69 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.03 | $6.33 |
| 52 Week High | $9.40 | $14.20 |
| Indicator | XMAX | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 40.97 | 39.01 |
| Support Level | $3.03 | $6.54 |
| Resistance Level | $9.16 | $7.85 |
| Average True Range (ATR) | 0.97 | 0.46 |
| MACD | 0.06 | -0.03 |
| Stochastic Oscillator | 53.49 | 15.88 |
XMax Inc is a designer and lifestyle furniture company. The company is a designer and distributor of contemporary styled residential and commercial furniture. The firms marketing and sales platform offers retail as well as online selection and purchase fulfillment internationally. The company also sells managed a variety of bedding foundation components. Its collection of lifestyle furniture brands includes Diamond Sofa. The firm's products are made in the United States and Asia. The company plans expansion into artificial intelligence (AI) while continuing to operate and develop its existing furniture business.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.